In ALK-positive and ALK-negative ALCL, BV-CHP is the recommended first-line therapy, while ASCT consolidation should be considered for ALK-negative ALCL and high-risk ALK-positive cases, particularly those with high-risk IPI, extranodal involvement, or residual disease (84). The gene discussed is ALK; the disease is anaplastic large cell lymphoma.